Bladder cancer trials in Netherlands

In Netherlands 33 Also abroad 626

33 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Where
Amsterdam
Age
18 years and over
People
45 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07222488 · EU 2025-520467-40-00
Phase 3Taking people
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Where
Amsterdam, Maastricht, Nieuwegein, Nijmegen, Rotterdam, Tilburg, Zwolle
Age
18 years and over
People
590 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07419295 · EU 2024-520014-22-00
Phase 1Taking people
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Where
GE Rotterdam
Age
18 years and over
People
677 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05614739 · EU 2022-502755-59-00
Phase 3Taking people
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Where
Nijmegen, Rotterdam, Utrecht
Age
18 years and over
People
220 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06919965 · EU 2024-519493-39-00
Phase 2/3Taking people
Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC.
Where
Amsterdam, Maastricht, Nijmegen, Rotterdam, Utrecht
Age
18 years and over
People
343 worldwide
Run by
Daiichi Sankyo Inc.
See details and how to join2024-516906-47-00 · EU 2024-516906-47-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Amsterdam, Groningen, Leiden, Maastricht, Nijmegen
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Amsterdam, Groningen, Nijmegen, Rotterdam, Utrecht
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 2Taking people
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
Where
Amsterdam, Rotterdam
Age
18 years and over
People
150 worldwide
Run by
AstraZeneca
See details and how to joinNCT06960577 · EU 2024-519246-75-01
Phase 3Taking people
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Where
Amsterdam, Breda, Nijmegen, Rotterdam
Age
18 years and over
People
450 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07218380 · EU 2025-522855-25-00
Phase 2Not yet taking people in Netherlands
A study investigating whether it is possible to preserve the bladder in participants with bladder cancer by starting with the drugs enfortumab vedotin plus pembrolizumab, followed by further treatment of the bladder depending on the effect on the bladder tumor: FIDELIO
Where
Amsterdam, Leiden, Utrecht
Age
18 years and over
People
56
Run by
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
See details and how to join2026-525965-29-00 · EU 2026-525965-29-00
Phase 2Not yet taking people in Netherlands
Feasibility study of Neo-adjuvant (before surgery) versus Adjuvant (after surgery) chemotherapy in Upper Tract Urothelial Carcinoma
Where
Amsterdam, Leiden, Nijmegen
Age
18 years and over
People
196 worldwide
Run by
European Uro-Oncology Group Stichting
See details and how to joinNCT02969083 · EU 2024-514991-41-01
Phase 1/2Taking people
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Where
Amsterdam, Rotterdam
Age
18 years and over
People
55 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07232602 · EU 2025-522253-19-00
Phase 2Taking people
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Where
Arnhem, Rotterdam
Age
18 years and over
People
308 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06833073 · EU 2024-517335-46-00
No phaseTaking people
Prospective Bladder Cancer Infrastructure (ProBCI)
Where
Almelo, Amersfoort, Amsterdam, Arnhem, Breda, Dordrecht, Ede, Emmen, Groningen, Hoofddorp, Leeuwarden, Leiderdorp, Maastricht, Nijmegen, Rotterdam, 's-Hertogenbosch, Sittard, Tilburg, Utrecht, Venlo, Winterswijk, Zwolle
Age
18 years and over
People
3,600
Run by
Prospective Bladder Cancer Infrastructure Foundation
See details and how to joinNCT04503577
Phase 1/2Taking people
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
Where
Amsterdam
Age
18 years and over
People
20 worldwide
Run by
Ferring Pharmaceuticals
See details and how to joinNCT06668493 · EU 2024-514360-70-00
Phase 1Taking people
PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF E-VIM VACCINE CVX1 WITH OR WITHOUT ICI IN THE TREATMENT OF SUBJECTS WITH MUSCLE INVASIVE BLADDER CANCER (MIBC) OR LOCALIZED OR LOCALLY ADVANCED RENAL CELL CANCER (RCC).
Where
Amsterdam, Leiden, Rotterdam
Age
18 years and over
People
83
Run by
CimCure B.V.
See details and how to join2025-523781-25-00 · EU 2025-523781-25-00
Phase 1Taking people
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Where
Amsterdam
Age
18 years and over
People
383 worldwide
Run by
Iambic Therapeutics, Inc
See details and how to joinNCT06253871
Phase 1Taking people
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Where
Amsterdam
Age
18 years and over
People
150 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06644755
No phaseTaking people
Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)
Where
Amsterdam
Age
18 years and over
People
27
Run by
Amsterdam UMC, location VUmc
See details and how to joinNCT07782164
Phase 2/3Taking people
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Where
Amsterdam, Breda, Leeuwarden
Age
18 years and over
People
470 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07106762
Phase 2Taking people
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Where
Rotterdam
Age
8 years and over
People
254 worldwide
Run by
Fore Biotherapeutics
See details and how to joinNCT05503797 · EU 2024-513578-23-00
Phase 1/2Taking people
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Where
Amsterdam, Nijmegen, Rotterdam
Age
18 years and over
People
180 worldwide
Run by
Alentis Therapeutics AG
See details and how to joinNCT07169734 · EU 2025-521441-24-00
Phase 2Not yet taking people in Netherlands
Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC
Where
Amsterdam, Leiden, Utrecht
Age
18 years and over
People
56
Run by
The Netherlands Cancer Institute
See details and how to joinNCT07663747
Phase 1Taking people
A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK‑8294 Monotherapy in Advanced Solid Tumors
Where
Amsterdam, Nijmegen
Age
18 years and over
People
21
Run by
Merck Sharp & Dohme LLC
See details and how to join2024-516870-31-00 · EU 2024-516870-31-00
Phase 4Not yet taking people in Netherlands
Avelumab Short Maintenance Trial
Where
Alkmaar, Amsterdam, Arnhem, Breda, Deventer, Eindhoven, Enschede, Heerlen, Hoofddorp, Leiden, Nieuwegein, Nijmegen, Rotterdam, 's-Gravenhage, Tilburg, Zwolle
Age
18 years and over
People
121
Run by
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
See details and how to join2024-512975-11-01 · EU 2024-512975-11-01